Skip to main content

December 2015

 

 

academics

 

Clinical research courses

Opportunity for pharmacists (34 posts) at ESIC Model Hospital - government job

Online Applications through website of ESIC are invited for filling up the posts of Paramedical and Nursing Staff for Directorate (Medical) Delhi on regular basis by Direct Recruitment. The detail of  vacancies is as under

Opportunity for Medical Representative (6 Posts) in Zuventus - IK JOBS

Zuventus is driven by a team of professionals with exceptional performance record in previous assignments. Naturally there was no dearth of courage to set challenging goals and achieving them through conviction and confidence.

Post: Medical Representative

Vacancies for B.Pharm/M.Sc in research projects at Central Drug Research Institute - 7 posts

CSIR- Central Drug Research Institute (CSIR-CDRI), a premier drug research institute of India was inaugurated on 17th Feb 1951 by the then Prime Minister of India Pt. Jawaharlal Nehru with a vision to strengthen and advance the field of drug research and development in the country. The Institute has made significant accomplishments in the pursuit of its mission to New Drugs & Technologies for affordable healthcare for all, generation of knowledge base and nurturing future leaders for healthcare sector.

Opening in project of Drug-Resistant Cancer Cells at Central University of Rajasthan - Master of Pharmacy

Bioactive glass can be used in tooth fillings to reduce the ability of bacteria to attack composite tooth fillings, and perhaps even provide some of the minerals needed to replace those lost to tooth decay, engineers from Oregon State University said.

(adsbygoogle = window.adsbygoogle || []).push({});

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure. ARX-04 (sufentanil sublingual tablet, 30 mcg) is being developed for the treatment of moderate-to-severe acute pain in adult patients administered by a healthcare professional in a medically supervised setting.

Celgene Corporation announced the settlement of litigation with Natco Pharma Ltd. of India, Natco's U.S. partner, Arrow International Limited, and Arrow's parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide).

Openings for post of Pharmacists at Rajiv Gandhi International Airport - Salary 26000/month